A DNA Nanomachine Reverses Mitochondrial Dysfunction by Cascaded Drug Release to Treat Osteoarthritis
Advanced Functional Materials · 2025-08 · 35 (33)
DOI: 10.1002/adfm.202419261 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Functional Materials, online erschienen am 18.04.2025. Verfasst von Song Xue und 11 weiteren Autor:innen. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Shenzhen Science and Technology Innovation Program, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
Mitochondrial dysfunction in chondrocytes is closely associated with osteoarthritis (OA) progression. However, the underlying mechanism remains elusive, and targeted OA therapies are lacking. Here, it is demonstrated that mitochondrial calcium (mito‐Ca 2+ ) content and energy metabolism are dysregulated in OA. Accordingly, a DNA nanomachine (DNM) is developed for OA treatment by reversing the mitochondrial dysfunction. The DNM used a programmable tetrahedral framework and incorporated dual targeting, switching, and therapeutic motifs. The targeting motifs contained a collagen II‐targeting peptide and an adenosine triphophate (ATP) aptamer to enable precise delivery into cartilage and mitochondria, respectively. Overexpressed matrix metalloproteinases (MMPs) in OA microenvironment triggered the MMP‐cleavable peptide switch and induced the release of mitochondrial open reading frame of the 12S rRNA‐c to promote ATP production. This result further triggered the release of DS16570511 conjugated to a sequence partially hybridized with ATP aptamer, inhibiting mito‐Ca 2+ uniporter and mitigating mito‐Ca 2+ overload under chronic inflammation. By leveraging sequential roles in delivery targeting, switch triggering, and therapeutic release, the DNM synergistically promoted cellular energy metabolism, inhibited mito‐Ca 2+ overload, and maintained extracellular matrix homeostasis. Consequently, cartilage degradation is significantly delayed in an OA model after treatment. This approach paves avenues for developing novel strategies to combat OA progression.
Förderung
- National Natural Science Foundation of China
- Shenzhen Science and Technology Innovation Program
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Xue, S., Zhao, Y., Huang, S., Ruan, G., Chen, J., Huang, H., Wu, C., Li, J., Hu, W., Zhang, Y., Zhang, C., & Ding, C. (2025). A DNA Nanomachine Reverses Mitochondrial Dysfunction by Cascaded Drug Release to Treat Osteoarthritis. Advanced Functional Materials, 35(33). https://doi.org/10.1002/adfm.202419261
Vancouver
Xue S, Zhao Y, Huang S, Ruan G, Chen J, Huang H, et al. A DNA Nanomachine Reverses Mitochondrial Dysfunction by Cascaded Drug Release to Treat Osteoarthritis. Advanced Functional Materials. 2025;35(33). doi:10.1002/adfm.202419261
BibTeX
@article{Xue2025,
author = {Xue, Song and Zhao, Yang and Huang, Shiqian and Ruan, Guangfeng and Chen, Jianmao and Huang, Hong and Wu, Cuixi and Li, Jiang and Hu, Wei and Zhang, Yinan and Zhang, Chao and Ding, Changhai},
title = {A DNA Nanomachine Reverses Mitochondrial Dysfunction by Cascaded Drug Release to Treat Osteoarthritis},
journal = {Advanced Functional Materials},
year = {2025},
volume = {35},
number = {33},
doi = {10.1002/adfm.202419261}
}
EUVIMED